BeiGene (BEIGF)

Healthcare · Biotechnology
$21.95 +0.00% on the day Market cap $29.6B 52-week range $15.95 to $25.29 Prices as of Oct 7, 2026

What the price implies

A reverse DCF: instead of guessing a fair value, it asks what growth today's price already assumes. How it works.

Free cash flow growth the price needs
11% a year for 10 years

At a market value of $29.6B, BeiGene's free cash flow of $942M (fiscal 2025) would need to grow about 11% a year for the stock to be worth today's price.

Assumes a 9% discount rate and 3% growth after year 10, on free cash flow (operating cash flow minus capital spending) from BeiGene's SEC filings. Change any assumption, or model revenue and margins instead, in the Modeling tab, or try your own numbers in the reverse DCF calculator.

Implied by the price10.9% a year
Free cash flow, last – years—
Revenue, same period157.6% a year
Price to free cash flow31.4x

Fundamental grade

B

Five factors scored 1 to 9 from BEIGF's latest numbers, weighted into one grade. It describes the business, not whether the stock is a buy.

Valuation3
Profitability7
Growth9
Financial health7
Cash efficiency7

Key numbers

P/E (trailing)64.5x
P/E (forward)46.2x
Price / free cash flow31.4x
EV / EBITDA26.6x
Price / sales4.83x
Price / book6.22x
Revenue growth+29.6%
Operating margin15.1%
Net margin10.7%
Return on equity12.7%
Dividend yield—
Debt / equity0.77x

Results from SEC filings

Fiscal years, from BeiGene's 10-K filings. The deep dive has 15+ years, quarters and every line.

Fiscal year20212022202320242025
Revenue$1.2B$1.4B$2.5B$3.8B$5.3B
Net income-$1.5B-$2.0B-$882M-$645M$287M
Free cash flow-$1.6B-$1.8B-$1.7B-$633M$942M
EPS (diluted)-$1.21-$1.49-$0.65-$0.47$0.19
Operating margin-122.3%-126.4%-49.1%-14.9%8.4%

Where the revenue comes from

Revenue by products, fiscal 2025.

Product revenue, net$5.3B99%
Other revenue$61M1%

Superinvestors who own BEIGF

From each investor's latest 13F filing (what a 13F shows).

None of the superinvestors we track held BEIGF in their latest 13F.

Insider buying

Open-market purchases by BeiGene's executives and directors in the last 12 months, from SEC Form 4 filings. What insider buying tells you.

No open-market insider purchases of BEIGF in the last 12 months. Most insider activity is selling and option exercises, which aren't shown here.

Get an alert at your buy price

Pick the price you'd be interested at. We'll email you when BEIGF trades at or below it.

$

Free accounts get 3 price alerts. No card needed.

In the full deep dive

DCF fair value per share
Yearly return (IRR) at today's price
Growth implied by revenue and margins
15+ years of statements and quarters

Questions

What growth does BeiGene's stock price imply?

At a market value of $29.6B, BeiGene would need its free cash flow to grow about 11% a year for 10 years (discounted at 9%, 3% growth after that) to be worth today's price.

Are BeiGene insiders buying the stock?

No open-market insider purchases of BEIGF in the last 12 months, according to SEC Form 4 filings.

Prices and ratios as of Oct 7, 2026; statements from SEC filings. Information only, not investment advice. Superinvestor holdings come from 13F filings, which are filed up to 45 days after each quarter ends.